Home   Business   Article

Subscribe Now

Cyted’s Marcel Gehrung in Forbes’ ‘30 Under 30’ list

More news, no ads


Cyted’s Marcel Gehrung has been selected as one of Forbes ‘30 Under 30’ 2021 listings in the science & healthcare section.

Marcel Gehrung, co-founder and CEO of Cyted
Marcel Gehrung, co-founder and CEO of Cyted

Marcel, who is CEO, co-founded the digital detection of disease specialist in 2018 with CSO Prof Rebecca Fitzgerald, professor of cancer prevention at the University of Cambridge, and CMO Maria O’Donovan, who is lead pathologist for upper GI cancer and diagnostic cytology at Cambridge University Hospitals.

The company is based at the Platinum Building at St John’s Innovation Park. Marcel’s qualities have helped steer Cyted from stealth mode in 2019 to a force to be reckoned with in 2021.

Last year, Cyted had a £7.5m funding boost via an investment round led by Morningside Venture Capital, and then a £1.2m industrial challenge strategy fund from Innovate UK. In October, Cyted announced its acquisition of Huntingdon-based Pathognomics, which effectively brought crucial lab tests in-house.

In the 10 years since global media company Forbes published the first 30 Under 30 list, the world has changed dramatically, but it now has an established history of spotting young innovators, entrepreneurs and leaders on the verge of making it big.

Marcel Gehrung, co-founder and CEO of Cyted, is a Forbes ‘30 Under 30’ star. Picture: Keith Heppell
Marcel Gehrung, co-founder and CEO of Cyted, is a Forbes ‘30 Under 30’ star. Picture: Keith Heppell

The Forbes list citation reads: “Marcel Gehrung is the co-founder and CEO of Cyted Ltd, a company that uses artificial intelligence to find biomarkers that detect cancer and other diseases early. They have raised more than $11m in capital from grants and venture capital and have 30 full-time employees.”

Marcel, 29, told the Cambridge Independent: “It is an honour to have been selected for inclusion in such a prestigious scheme, alongside some of the most impactful young entrepreneurs in Europe.

“I am extremely grateful and excited to join the worldwide ‘Under 30’ community.”

Cyted’s initial focus is on early detection of Barrett’s oesophagus: cells and biomarkers associated with Barrett’s oesophagus are analysed using the Cyted pathology platform.

Non-executive director Martin Frost said: “Cyted is a great company and is moving quickly to fulfil its mission to revolutionise digital pathology.

“I love working alongside, contributing and learning from Marcel; he has a relentless drive and curiosity with a strong clinical and ethical approach – critical ingredients making up an impressive leader.”

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More